-
Security Type
-
Equity
-
Min Investment
-
$100
-
Location
-
San Francisco, CA
-
Offering Date
-
April 15, 2021
-
Expected Close Date
-
April 30, 2022
Company Description
We now know that aging is not inevitable. Over thirty years of research in the biology of aging using model organisms has shown that aging is plastic, tractable, and druggable—meaning it can be treated. It is our mission not only to increase health span and wellness, but to extend lifespan itself, well beyond what was once thought possible.
Perks
Invest $25,000+ Tour of the labs of Gerostate Alpha at the Buck Institute
Invest $50,000+ Tour of the labs of GSA at the Buck, plus a 1 on 1 presentation of our latest exciting results
Invest $150,000+ Tour of the labs, 1 on 1 presentation, dinner with the founders & peak into future tech development of GSA
Key Deal Facts
$2.1M raised in initial seed round, at $15M valuation
Team at the forefront of aging research for decades, collectively authoring 200+ papers
Our platform delivers drug candidates to slow aging at a success rate of 20%
Funds will be used to test 10-15 of our hits in aging mice
Executive chairman was former CEO of major pharma company, Sangamo Therapeutics
Management Team / Advisory Board Bios
Simon Melov, CEO
PhD; Professor at Buck Institute for Research on Aging & CEO of Gerostate Alpha
Mark S Lucanic, CTO
PhD; Expert in small molecule and genetic screens including significant experience with high throughput technologies, and has utilized simple model organisms to explore pharmacological extension of lifespan.
Gordon Lithgow Professor,, Vice President Buck Institute
PhD; Chief Academic Officer at the Buck Institute for Research on Aging and specializes in the properties of small molecules to extend lifespan, having been internationally recognized for his work on aging with numerous awards and prizes.
